Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products

Paul J. Beisswenger, Scott K. Howell, Gregory B. Russell, Michael E. Miller, Stephen S. Rich, Michael Mauer

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Objective-Increased advanced glycation end products (AGEs) and oxidation products (OPs) are proposed to lead to progression of diabetic nephropathy (DN). We investigated the relationship between AGEs, OPs, and progression of DN in 103 subjects with type 1 diabetes participating in the Natural History of Diabetic Nephropathy Study. Researchdesign and methods-Mean age of subjects was 17.667.4 years, and mean duration of diabetes was 8.3 6 4.9 years. All patients were normoalbuminuric. Change in glomerular basement membrane (GBM) width from baseline to 5 years, measured using electron micrographs of renal biopsies, was our primary end point, and mesangial fractional volume was a secondary end point. Fast progressors (FPs) were defined as those in the upper quartile of GBM change, and the remaining patients were classified as slow progressors (SPs). AGEs (3-deoxyglucosone and methylglyoxal hydroimidazolones [MGHI]), carboxymethyl lysine (CML), carboxyethyl lysine (CEL), and OPs (methionine sulfoxide and 2-aminoadipic acid) were measured at year 5 by liquid chromatography/triple-quadruple mass spectroscopy on 10-K plasma filtrates. Results-We found that MGHI, CEL, and CML levels were significantly higher in FPs relative to SPs. No product predicted mesangial expansion. A model containing only HbA1c accounted for 4.7% of GBM width variation, with the total variability explained by the model increasing to 11.6% when MGHI, CEL, and CML were added to the regression model (7.9% increase).MGHI was a significant independent predictor of FP. Using a logistic regression model to relate each biomarker to the probability of a subject's classification as an FP, CML, CEL, and MGHI, but not HbA1c, showed a significant relationship to the probability of FP. Conclusions-The results suggest that these threemajor AGEs may be early indicators of progression of important DN lesions.

Original languageEnglish (US)
Pages (from-to)3234-3239
Number of pages6
JournalDiabetes Care
Volume36
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Pyruvaldehyde
Advanced Glycosylation End Products
Diabetic Nephropathies
Glomerular Basement Membrane
Lysine
2-Aminoadipic Acid
Logistic Models
Type 1 Diabetes Mellitus
Liquid Chromatography
Mass Spectrometry
Biomarkers
imidazolone
Electrons
Kidney
Biopsy
N(6)-carboxymethyllysine

Cite this

Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products. / Beisswenger, Paul J.; Howell, Scott K.; Russell, Gregory B.; Miller, Michael E.; Rich, Stephen S.; Mauer, Michael.

In: Diabetes Care, Vol. 36, No. 10, 01.10.2013, p. 3234-3239.

Research output: Contribution to journalArticle

Beisswenger, Paul J. ; Howell, Scott K. ; Russell, Gregory B. ; Miller, Michael E. ; Rich, Stephen S. ; Mauer, Michael. / Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products. In: Diabetes Care. 2013 ; Vol. 36, No. 10. pp. 3234-3239.
@article{6ba5662cc65645a4bbc3581275ca003a,
title = "Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products",
abstract = "Objective-Increased advanced glycation end products (AGEs) and oxidation products (OPs) are proposed to lead to progression of diabetic nephropathy (DN). We investigated the relationship between AGEs, OPs, and progression of DN in 103 subjects with type 1 diabetes participating in the Natural History of Diabetic Nephropathy Study. Researchdesign and methods-Mean age of subjects was 17.667.4 years, and mean duration of diabetes was 8.3 6 4.9 years. All patients were normoalbuminuric. Change in glomerular basement membrane (GBM) width from baseline to 5 years, measured using electron micrographs of renal biopsies, was our primary end point, and mesangial fractional volume was a secondary end point. Fast progressors (FPs) were defined as those in the upper quartile of GBM change, and the remaining patients were classified as slow progressors (SPs). AGEs (3-deoxyglucosone and methylglyoxal hydroimidazolones [MGHI]), carboxymethyl lysine (CML), carboxyethyl lysine (CEL), and OPs (methionine sulfoxide and 2-aminoadipic acid) were measured at year 5 by liquid chromatography/triple-quadruple mass spectroscopy on 10-K plasma filtrates. Results-We found that MGHI, CEL, and CML levels were significantly higher in FPs relative to SPs. No product predicted mesangial expansion. A model containing only HbA1c accounted for 4.7{\%} of GBM width variation, with the total variability explained by the model increasing to 11.6{\%} when MGHI, CEL, and CML were added to the regression model (7.9{\%} increase).MGHI was a significant independent predictor of FP. Using a logistic regression model to relate each biomarker to the probability of a subject's classification as an FP, CML, CEL, and MGHI, but not HbA1c, showed a significant relationship to the probability of FP. Conclusions-The results suggest that these threemajor AGEs may be early indicators of progression of important DN lesions.",
author = "Beisswenger, {Paul J.} and Howell, {Scott K.} and Russell, {Gregory B.} and Miller, {Michael E.} and Rich, {Stephen S.} and Michael Mauer",
year = "2013",
month = "10",
day = "1",
doi = "10.2337/dc12-2689",
language = "English (US)",
volume = "36",
pages = "3234--3239",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "10",

}

TY - JOUR

T1 - Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products

AU - Beisswenger, Paul J.

AU - Howell, Scott K.

AU - Russell, Gregory B.

AU - Miller, Michael E.

AU - Rich, Stephen S.

AU - Mauer, Michael

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Objective-Increased advanced glycation end products (AGEs) and oxidation products (OPs) are proposed to lead to progression of diabetic nephropathy (DN). We investigated the relationship between AGEs, OPs, and progression of DN in 103 subjects with type 1 diabetes participating in the Natural History of Diabetic Nephropathy Study. Researchdesign and methods-Mean age of subjects was 17.667.4 years, and mean duration of diabetes was 8.3 6 4.9 years. All patients were normoalbuminuric. Change in glomerular basement membrane (GBM) width from baseline to 5 years, measured using electron micrographs of renal biopsies, was our primary end point, and mesangial fractional volume was a secondary end point. Fast progressors (FPs) were defined as those in the upper quartile of GBM change, and the remaining patients were classified as slow progressors (SPs). AGEs (3-deoxyglucosone and methylglyoxal hydroimidazolones [MGHI]), carboxymethyl lysine (CML), carboxyethyl lysine (CEL), and OPs (methionine sulfoxide and 2-aminoadipic acid) were measured at year 5 by liquid chromatography/triple-quadruple mass spectroscopy on 10-K plasma filtrates. Results-We found that MGHI, CEL, and CML levels were significantly higher in FPs relative to SPs. No product predicted mesangial expansion. A model containing only HbA1c accounted for 4.7% of GBM width variation, with the total variability explained by the model increasing to 11.6% when MGHI, CEL, and CML were added to the regression model (7.9% increase).MGHI was a significant independent predictor of FP. Using a logistic regression model to relate each biomarker to the probability of a subject's classification as an FP, CML, CEL, and MGHI, but not HbA1c, showed a significant relationship to the probability of FP. Conclusions-The results suggest that these threemajor AGEs may be early indicators of progression of important DN lesions.

AB - Objective-Increased advanced glycation end products (AGEs) and oxidation products (OPs) are proposed to lead to progression of diabetic nephropathy (DN). We investigated the relationship between AGEs, OPs, and progression of DN in 103 subjects with type 1 diabetes participating in the Natural History of Diabetic Nephropathy Study. Researchdesign and methods-Mean age of subjects was 17.667.4 years, and mean duration of diabetes was 8.3 6 4.9 years. All patients were normoalbuminuric. Change in glomerular basement membrane (GBM) width from baseline to 5 years, measured using electron micrographs of renal biopsies, was our primary end point, and mesangial fractional volume was a secondary end point. Fast progressors (FPs) were defined as those in the upper quartile of GBM change, and the remaining patients were classified as slow progressors (SPs). AGEs (3-deoxyglucosone and methylglyoxal hydroimidazolones [MGHI]), carboxymethyl lysine (CML), carboxyethyl lysine (CEL), and OPs (methionine sulfoxide and 2-aminoadipic acid) were measured at year 5 by liquid chromatography/triple-quadruple mass spectroscopy on 10-K plasma filtrates. Results-We found that MGHI, CEL, and CML levels were significantly higher in FPs relative to SPs. No product predicted mesangial expansion. A model containing only HbA1c accounted for 4.7% of GBM width variation, with the total variability explained by the model increasing to 11.6% when MGHI, CEL, and CML were added to the regression model (7.9% increase).MGHI was a significant independent predictor of FP. Using a logistic regression model to relate each biomarker to the probability of a subject's classification as an FP, CML, CEL, and MGHI, but not HbA1c, showed a significant relationship to the probability of FP. Conclusions-The results suggest that these threemajor AGEs may be early indicators of progression of important DN lesions.

UR - http://www.scopus.com/inward/record.url?scp=84888108332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888108332&partnerID=8YFLogxK

U2 - 10.2337/dc12-2689

DO - 10.2337/dc12-2689

M3 - Article

VL - 36

SP - 3234

EP - 3239

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 10

ER -